Welcome
Support Centre
21 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A Pilot Study of the Effect of a Hypertonic Saline/Dextran (HSD) Solution Compared to Mannitol in the Management of Raised Intracranial Pressure (ICP)
ISRCTN ISRCTN82121210
ClinicalTrials.gov identifier
Public title A Pilot Study of the Effect of a Hypertonic Saline/Dextran (HSD) Solution Compared to Mannitol in the Management of Raised Intracranial Pressure (ICP)
Scientific title
Acronym N/A
Serial number at source N0185139336
Study hypothesis Whether hypertonic saline/dextran produces greater lowering of raised intracranial pressure and for a longer duration that an equiosmolar dose of mannitol.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Injury, Occupational Diseases, Poisoning: Brain
Participants - inclusion criteria Not provided at time of registration
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/11/2001
Anticipated end date 31/12/2004
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Patients on the intensive care unit with brain injury and an intracranial monitor fitted will be eligible for entry into the study. Those with persistently elevated ICP despite usual management will be randomised to receive either mannitol 0.25 g/kg (the standard treatment at this point) or an equiosmolar dose of HSD. ICP will be recorded each minute using the standard ICU monitors. Patients will be eligible to receive up to three doses of the drug (Mannitol or HSD) if their clinical condition warrants it and there are no contra-indications. ICP will be monitored, for the purposes of the study, until eight hours since the last dose of HSD/mannitol.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Plymouth Hospitals NHS Trust
Trial website
Publications
Contact name Dr  P D  Macnaughton
  Address Intensive Care Unit,
Level 04
Derriford Hospital
Derriford
  City/town Plymouth
  Zip/Postcode PL6 8DH
  Country United Kingdom
  Tel +44 (0)1752 792555
  Fax +44 (0)1752 763287
  Email peter.macnaughton@phnt.swest.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
  Address The Department of Health, Richmond House, 79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2004
Last edited 03/01/2006
Date ISRCTN assigned 30/09/2004
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central